Since almost no tumors expressed GPC3, and all adenocarcinomas expressed CK19, we did not carry out clinical follow-up or a statistical analysis to correlate the expression of these markers with stage, grade, or overall survival. This evidence concerns the gene GPC3 and adenocarcinoma.